Table 3.
Odds ratio (95% CI) of the variables identified in the multivariate analyses as predictors of clinically beneficial goals after six and 6–12 months of GLP-1RA treatment initiation.
| Clinical Variable | After 6 Months | After 6–12 Months | ||||||
|---|---|---|---|---|---|---|---|---|
| Reduction in HbA1c ≥ 1% | Reduction in Weight ≥ 3% | Reduction in HbA1c ≥ 1% AND Weight ≥ 3% | Reduction in HbA1c ≥ 1%, Weight ≥ 3%OR Both | Reduction in HbA1c ≥ 1% | Reduction in Weight ≥ 3% | Reduction in HbA1c ≥ 1% AND Weight ≥ 3% | Reduction in HbA1c ≥ 1%, Weight ≥ 3%OR Both | |
| Male gender | – | – | – | – | – | 0.73 (0.54–0.97) p = 0.036 |
– | – |
|
T2D duration
(10–20 years) |
0.64 (0.43–0.97) p = 0.036 |
– | – | 0.67 (0.46–0.96) p = 0.031 |
– | – | 2.81* (1.02-7.61) p = 0.042 |
– |
| HbA1c | 2.06 (1.83–2.33) p < 0.001 |
– | 1.25 (1.12–1.40) p < 0.001 |
1.41 (1.28–1.56) p < 0.001 |
2.14 (1.85–2.48) p < 0.001 |
– | 1.42 (1.22–1.66) p < 0.001 |
1.35 (1.22–1.50) p < 0.001 |
| BMI | – | 1.03 (1.01–1.05) p = 0.014 |
1.03 (1.00–1.06) p = 0.032 |
1.02 (1.00–1.05) p = 0.043 |
– | 1.04 (1.02–1.07) p = 0.001 |
1.06 (1.02–1.10) p = 0.003 |
1.03 (1.01–1.06) p = 0.005 |
| DBP | – | – | – | – | – | – | 1.03 (1.01–1.06) p = 0.018 |
– |
| eGFR | – | – | – | – | – | – | 1.01 (1.00–1.03) p = 0.042 |
– |
| Prescribed according to HPR | – | – | – | 1.60 (1.04-2.45) p = 0.031 |
– | – | – | – |
| AUC of the model | 0.78 | 0.61 | 0.67 | 0.68 | 0.79 | 0.63 | 0.74 | 0.67 |
| (0.76–0.79) | (0.59–0.62) | (0.65–0.69) | (0.66–0.69) | (0.77–0.80) | (0.61–0.65) | (0.71–0.76) | (0.65–0.68) | |
* T2D duration > 20 years. BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate using the CDK-Epi equation; HbA1c, glycated haemoglobin A1c; HPR, health policy requirements for reimbursement